AUS
NZ
UK
CA
USA
IND
Highlights
- Anteris Technologies receives a significant R&D tax refund.
- The company focuses on advancing heart-related technologies.
- Funding supports development and clinical trials for innovative devices.
Anteris Technologies Ltd (ASX:AVR) has been awarded an A$1.4 million tax refund under the Australian Government’s Research and Development (R&D) Tax Incentive Scheme. This financial boost comes as the ASX healthcare stock continues to advance its research efforts in developing groundbreaking technologies for treating heart conditions.
The R&D tax refund covers eligible research activities for the year ending December 31, 2023. This scheme, designed to encourage innovation, allows Australian companies to receive a refundable tax offset, which helps recover a portion of the expenses incurred in their research and development efforts.
Focus on Medical Innovation
Anteris Technologies plans to use the A$1.4 million refund to further the development of its key medical technologies. These include the ADAPT® tissue, DurAVR® transcatheter heart valve (THV), and the ComASUR® Delivery System. These innovations are crucial to the company's efforts in addressing unmet needs within the structural heart market.
A notable project on the horizon for Anteris is its upcoming FDA pivotal trial for the DurAVR® THV. This trial will focus on the treatment of severe aortic stenosis, a condition where the heart’s aortic valve narrows, limiting blood flow and causing significant health issues. With support from this tax refund, Anteris is better positioned to move forward with the trial and further its development pipeline.
Leading Solutions in the Structural Heart Market
Anteris Technologies has established itself as a leader in the structural heart market by creating solutions that address critical health challenges. Its DurAVR® transcatheter heart valve stands out as the first device of its kind to utilize a single piece of bioengineered tissue. This design mimics the function of a healthy human valve, offering improved outcomes for patients.
The company’s collaborative approach, working alongside top cardiologists and cardiac surgeons, ensures that its products are developed with a deep understanding of clinical needs. The R&D tax refund provides critical financial support that allows Anteris to maintain its momentum in developing cutting-edge technologies and advancing clinical trials.
With these funds, Anteris continues to work toward offering superior treatment options for patients facing heart diseases, particularly those with severe aortic stenosis, where current treatment options are limited. The company remains focused on pushing the boundaries of medical innovation with the help of government incentives like the R&D tax refund.
